You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The MiQLab system can look for 27 different targets, allowing the detection of SARS-CoV-2 as well as the determination of specific variants.
The company has performed 100,000 rapid tests for SARS-CoV-2 to date for a variety of organizations, including sports leagues and public schools.
The firm submitted its SARS-CoV-2 saliva test on its Pelican device to the US Food and Drug Administration for Emergency Use Authorization this week.
The test uses isothermal nucleic acid amplification to return results in 20 minutes at the point of care, and demonstrated 98 percent agreement with PCR testing.
Roche has invested CHF 600 million ($664 million) in manufacturing to add 90 manufacturing lines and has plans to launch 17 new tests in 2021.
The company has two COVID-19 tests: One, a moderate high-complexity test, received EUA in September, while the other is in clinical trials.
The company emphasized on its earnings call that decentralization of laboratory testing is a key component of its long-term strategy.
The company has developed an analyzer to run PCR, immunochemistry, and cytometry tests at the same time for a variety of diseases including COVID-19.
Under the plan, the president will establish a national pandemic testing board to oversee implementation of a unified approach to testing.
The company is also working in parallel on an at-home test that would be over the counter and return results within an hour.
